A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Heart Failure, sponsored by Bayer. Completed at 661 sites in 37 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.
Among the 23 studies testing finerenone in Heart Failure, this one has the largest enrollment, is the only one that started in 2020, is one of 9 in phase 3, and was the 5th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages up to 18
Juntendo University · Sites in Japan
Ages 18+
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages 6 mo–17 yrs
Colorado Prevention Center · Sites in United States, Argentina, Brazil and 11 more countries
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,016 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 120 across the 23 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
47 studies in Heart Failure by Bayer: 6 open now, 7 under way, 2 of them phase 3. Of 40 finished, 9 (23%) have results posted.
Among the 47 studies in Heart Failure by Bayer, this one has the largest enrollment of the 33 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 3, and was the 22nd registered.
Bayer’s Heart Failure studies by the year they started, since 2007.
5 of the studies testing finerenone in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT06059664University of North Carolina, Chapel HillThe EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | 2027-03-31 |
| NCT07830940Assiut UniversityFinerenone and Cardiac Remodeling in HFpEF | 2027-09-25 |
| NCT07583173China National Center for Cardiovascular DiseasesEffect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies testing finerenone in Heart Failure, from their registry updates:
Among Bayer’s 47 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. The study plans to enroll 6000 male and female patients of the age of 40 years and above suffering from heart failure with ejection fraction greater than or equal to 40%. Participants will take the study product as oral tablet with a dose between 0 (Placebo) 40 mg once daily. Study duration will be up to 43 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
n-terminal prohormone B-type natriuretic peptide (NT-proBNP) ≥300 pg/mL (BNP ≥100 pg/mL) in sinus rhythm and patient does not have an ongoing diagnosis of paroxysmal atrial fibrillation or NT-proBNP ≥900 pg/mL (BNP ≥300 pg/mL) in atrial fibrillation (or if atrial fibrillation status is unknown or if patient has an ongoing diagnosis of paroxysmal atrial fibrillation) for participants obtained at the following time:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients receive BAY94-8862
Drug: Finerenone (BAY94-8862)
Adult patients receive placebo
Other: Placebo
For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets.
Placebo tablets matching BAY94-8862 are administered orally.
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events
Number of composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.
Time frame: From randomization up until the end of study, with an average study duration of 32 months
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events
Number of participants with composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.
Time frame: From randomization up until the end of study, with an average study duration of 32 months
Occurrence of Total (First and Recurrent) Heart Failure Events
Number of total (first and recurrent) heart failure events.
Time frame: From randomization up until the end of study, with an average study duration of 32 months
Occurrence of Total (First and Recurrent) Heart Failure Events
Number of participants with total (first and recurrent) heart failure events.
Time frame: From randomization up until the end of study, with an average study duration of 32 months
Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) is ranged from 0 to 100. A higher score (closer to 100) reflects fewer symptoms, indicating better heart failure symptom status. For the change from baseline the combined and averaged result across the entire time frame is reported.
Time frame: From baseline to Month 6, 9 and 12
Proportion of Participants Who Showed Improvement in NHYA Class
The New York Heart Association (NYHA) Functional Classification is a simple scale that classifies patients with heart failure based on the severity of their symptoms and how those symptoms affect their physical activity, which ranges from Class I to Class IV, a lower class number is indicative of a better condition. A patient was considered as having improved in NYHA class, if the NYHA class at Month 12 is at least one category improved compared to the baseline visit.
Time frame: from baseline to Month 12
First Occurrence of Renal Composite Events
Number of participants with renal composite events encompassing the components sustained decrease in eGFR ≥50% relative to baseline over at least 4 weeks, sustained eGFR decline to \<15 mL/min/1.73 m2 over at least 4 weeks, initiation of chronic dialysis and renal transplantation.
Time frame: From randomization up to end of study visit, with an average study duration of 32 months
Occurence of All-cause Mortality (Full Analysis Set)
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
Time frame: From randomization until end of study, with an average of 32 months
Study was conducted at multiple centers in 37 countries/regions between 14-Sep-2020 (first participant first visit) and 14-Jun-2024 (last participant last visit).
| Milestone | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Started | 3011 | 3005 |
| Valid for fas | 3003 | 2998 |
| Completed | 2996 | 2986 |
| Not completed | 15 | 19 |
| Withdrew: Lost to follow-up | 1 | 5 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Major gcp violations | 8 | 7 |
Number of composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.
| events | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | 1083 | 1283 |
Number of participants with composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.
| Participants | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | 624 | 719 |
Number of total (first and recurrent) heart failure events.
| events | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Occurrence of Total (First and Recurrent) Heart Failure Events | 842 | 1024 |
Number of participants with total (first and recurrent) heart failure events.
| Participants | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Occurrence of Total (First and Recurrent) Heart Failure Events | 479 | 573 |
The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) is ranged from 0 to 100. A higher score (closer to 100) reflects fewer symptoms, indicating better heart failure symptom status. For the change from baseline the combined and averaged result across the entire time frame is reported.
| score on scale | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) | 7.99 (7.37 to 8.62) | 6.43 (5.79 to 7.07) |
The New York Heart Association (NYHA) Functional Classification is a simple scale that classifies patients with heart failure based on the severity of their symptoms and how those symptoms affect their physical activity, which ranges from Class I to Class IV, a lower class number is indicative of a better condition. A patient was considered as having improved in NYHA class, if the NYHA class at Month 12 is at least one category improved compared to the baseline visit.
| Estimated proportion | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Proportion of Participants Who Showed Improvement in NHYA Class | 0.179 (0.163 to 0.195) | 0.178 (0.162 to 0.194) |
Number of participants with renal composite events encompassing the components sustained decrease in eGFR ≥50% relative to baseline over at least 4 weeks, sustained eGFR decline to \<15 mL/min/1.73 m2 over at least 4 weeks, initiation of chronic dialysis and renal transplantation.
| Participants | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| First Occurrence of Renal Composite Events | 75 | 55 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
| Participants | Finerenone (BAY94-8862) | Placebo |
|---|---|---|
| Occurence of All-cause Mortality (Full Analysis Set) | 491 | 522 |
Collected over Treatment emergent adverse events (TEAEs) are considered from the start of study intervention up to 3 days after the last study intervention administration, with an average treatment duration of 28 months. In contrast, numbers for all-cause mortality listed below consider all deaths after randomization over the entire average study duration of 32 months, independent of treatment and including deaths which occurred after the end of study visit in the 4-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone (BAY94-8862) | 494/2,993 (16.5%) | 1,157/2,993 (38.7%) | 1,317/2,993 (44%) |
| Placebo | 528/2,993 (17.6%) | 1,213/2,993 (40.5%) | 1,228/2,993 (41%) |
| Never Received Treatment | 3/15 (20%) | 0/15 (0%) | 0/15 (0%) |
| Event | Finerenone (BAY94-8862) | Placebo | Never Received Treatment |
|---|---|---|---|
| PneumoniaInfections and infestations | 87/2993 | 110/2993 | 0/15 |
| Atrial fibrillationCardiac disorders | 77/2993 | 73/2993 | 0/15 |
| COVID-19Infections and infestations | 69/2993 | 71/2993 | 0/15 |
| Acute kidney injuryRenal and urinary disorders | 54/2993 | 28/2993 | 0/15 |
| DeathGeneral disorders | 29/2993 | 52/2993 | 0/15 |
| Angina unstableCardiac disorders | 38/2993 | 36/2993 | 0/15 |
| AnaemiaBlood and lymphatic system disorders | 34/2993 | 31/2993 | 0/15 |
| COVID-19 pneumoniaInfections and infestations | 28/2993 | 30/2993 | 0/15 |
| Urinary tract infectionInfections and infestations | 29/2993 | 26/2993 | 0/15 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 18/2993 | 27/2993 | 0/15 |
| Event | Finerenone (BAY94-8862) | Placebo | Never Received Treatment |
|---|---|---|---|
| COVID-19Infections and infestations | 292/2993 | 297/2993 | 0/15 |
| HyperkalaemiaMetabolism and nutrition disorders | 252/2993 | 107/2993 | 0/15 |
| HypotensionVascular disorders | 210/2993 | 128/2993 | 0/15 |
| HypokalaemiaMetabolism and nutrition disorders | 88/2993 | 196/2993 | 0/15 |
| Renal impairmentRenal and urinary disorders | 193/2993 | 110/2993 | 0/15 |
| HypertensionVascular disorders | 103/2993 | 179/2993 | 0/15 |
| DizzinessNervous system disorders | 170/2993 | 137/2993 | 0/15 |
| AnaemiaBlood and lymphatic system disorders | 169/2993 | 162/2993 | 0/15 |
| Cardiac failureCardiac disorders | 116/2993 | 168/2993 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 167/2993 | 129/2993 | 0/15 |
| Age, Continuous(Years) | Finerenone (BAY94-8862) | Placebo | Total |
|---|---|---|---|
| Mean | 71.94 ± 9.60 | 72.04 ± 9.69 | 71.99 ± 9.65 |
| Sex: Female, Male(Participants) | Finerenone (BAY94-8862) | Placebo | Total |
|---|---|---|---|
| Female | 1355 | 1377 | 2732 |
| Male | 1648 | 1621 | 3269 |
| Race (NIH/OMB)(Participants) | Finerenone (BAY94-8862) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 75 | 74 | 149 |
| Asian | 497 | 499 | 996 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 49 | 39 | 88 |
| White | 2366 | 2369 | 4735 |
| More than one race | 7 | 8 | 15 |
| Unknown or Not Reported | 8 | 9 | 17 |
| NYHA class(Participants) | Finerenone (BAY94-8862) | Placebo | Total |
|---|---|---|---|
| NYHA class II | 2081 | 2065 | 4146 |
| NYHA class III | 903 | 910 | 1813 |
| NYHA class IV | 18 | 23 | 41 |
| missing | 1 | 0 | 1 |
| Baseline LVEF(percentage of ejection fraction) | Finerenone (BAY94-8862) | Placebo | Total |
|---|---|---|---|
| Mean | 52.64 ± 7.82 | 52.49 ± 7.81 | 52.56 ± 7.81 |
Showing the first 100 of 661 sites across 37 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Sep 2020 to primary completion in May 2024, 44 months.
Results were first posted in Aug 2025, 1 year 3 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 44 months is above that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone